VNDA logo

Vanda Pharmaceuticals Inc.

VNDA

VNDA: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

more

Show VNDA Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of VNDA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by VNDA's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $40,000 Oct 19, 2021 Issue: Pharmacy
  • $40,000 Jul 19, 2021 Issue: Pharmacy
  • $40,000 Apr 16, 2021 Issue: Pharmacy
  • $40,000 Jan 19, 2021 Issue: Pharmacy
  • $40,000 Oct 14, 2020 Issue: Pharmacy
  • $40,000 Jul 16, 2020 Issue: Pharmacy
  • $40,000 Apr 20, 2020 Issue: Pharmacy
  • $40,000 Jan 21, 2020 Issue: Pharmacy
U.S. Patents

New patents grants

  • Patent Title: Highly purified pharmaceutical grade tasimelteon Sep. 19, 2023
  • Patent Title: Liquid tasimelteon formulations and methods of use thereof Sep. 19, 2023
  • Patent Title: Multiple myeloma treatment Aug. 29, 2023
  • Patent Title: Treatment of schizophrenia Aug. 15, 2023
  • Patent Title: Cancer treatment Jun. 06, 2023
  • Patent Title: Treatment of circadian rhythm disorders Apr. 25, 2023
  • Patent Title: Method of treatment of schizophrenia Mar. 21, 2023
  • Patent Title: Highly purified pharmaceutical grade tasimelteon Jan. 31, 2023
  • Patent Title: Treatment of atopic dermatitis with tradipitant Jan. 10, 2023
  • Patent Title: Treatment of cyr61- and vegf-mediated conditions Oct. 04, 2022
  • Patent Title: Method of improving sleep Oct. 04, 2022
  • Patent Title: Method for improving or enhancing cognition Sep. 06, 2022
  • Patent Title: Method of treatment with tradipitant May. 10, 2022
  • Patent Title: Treatment of circadian rhythm disorders Mar. 29, 2022
  • Patent Title: Method of treatment Mar. 08, 2022
  • Patent Title: Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone Jan. 04, 2022
  • Patent Title: Highly purified pharmaceutical grade tasimelteon Dec. 21, 2021
  • Patent Title: Liquid tasimelteon formulations and methods of use thereof Dec. 21, 2021
  • Patent Title: Method of treatment Oct. 12, 2021
  • Patent Title: Treatment of circadian rhythm disorders Aug. 17, 2021
  • Patent Title: Cancer treatment Aug. 03, 2021
  • Patent Title: Treatment of schizophrenia Jul. 27, 2021
  • Patent Title: Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype Jul. 13, 2021
  • Patent Title: Method of treatment May. 25, 2021
  • Patent Title: Iloperidone for the treatment of schizophrenia Apr. 27, 2021
  • Patent Title: Treatment of circadian rhythm disorders Apr. 20, 2021
  • Patent Title: Treatment of circadian rhythm disorders Mar. 16, 2021
  • Patent Title: Iloperidone metabolite for use in the treatment of psychiatric disorders Dec. 29, 2020
  • Patent Title: Highly purified pharmaceutical grade tasimelteon Nov. 10, 2020
  • Patent Title: Use of tradipitant in motion sickness Nov. 03, 2020
  • Patent Title: Method of treatment with tradipitant Sep. 15, 2020
  • Patent Title: Method of treatment May. 19, 2020
  • Patent Title: Method of predicting a predisposition to qt prolongation Feb. 25, 2020
  • Patent Title: Method of predicting a predisposition to qt prolongation Feb. 25, 2020
  • Patent Title: Method of predicting a predisposition to qt prolongation Feb. 18, 2020
  • Patent Title: Method of predicting a predisposition to qt prolongation Feb. 18, 2020
  • Patent Title: Method of treatment with tradipitant Nov. 05, 2019
  • Patent Title: Treatment of circadian rhythm disorders Oct. 22, 2019
  • Patent Title: Iloperidone for the treatment of schizophrenia Oct. 15, 2019
  • Patent Title: Method of treatment Aug. 13, 2019
  • Patent Title: Methods for the administration of iloperidone Apr. 30, 2019
  • Patent Title: Method and composition for treating an alpha adrenoceptor-mediated condition Apr. 30, 2019
  • Patent Title: Cancer treatment Apr. 23, 2019
  • Patent Title: Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide Mar. 19, 2019
  • Patent Title: Method of treatment Jan. 15, 2019
  • Patent Title: Treatment of circadian rhythm disorders Dec. 11, 2018
  • Patent Title: Highly purifid pharmaceutical grade tasimelteon Sep. 11, 2018
  • Patent Title: Method and composition for treating a serotonin receptor-mediated condition Jun. 05, 2018
  • Patent Title: Treatment of circadian rhythm disorders Jan. 02, 2018
  • Patent Title: Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide Dec. 26, 2017
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of VNDA in WallStreetBets Daily Discussion

VNDA News

Recent insights relating to VNDA

CNBC Recommendations

Recent picks made for VNDA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VNDA

Corporate Flights

Flights by private jets registered to VNDA